L-asparaginase related hyperglycemia

Area of Science:

• Oncology
• Pediatric Hematology
• Pharmacology

Background:

• L-asparaginase is a key chemotherapeutic agent for acute lymphoblastic leukemia (ALL).
• Hyperglycemia is a recognized adverse effect of L-asparaginase treatment.
• The study investigates hyperglycemia incidence and management during ALL induction therapy.

Purpose of the Study:

• To assess the occurrence and characteristics of hyperglycemia in pediatric patients with ALL receiving L-asparaginase.
• To evaluate the impact of hyperglycemia on treatment continuation and patient outcomes.
• To emphasize the importance of vigilant monitoring for hyperglycemia during L-asparaginase therapy.

Main Methods:

• Prospective observation of 14 pediatric patients undergoing ALL induction therapy.
• Treatment regimen included L-asparaginase, prednisolone, vincristine, and daunorubicin.
• Hyperglycemia was monitored, and L-asparaginase type was noted (E. coli vs. Erwinia).

Main Results:

• Hyperglycemia developed in 14/14 patients after a mean of 5 L-asparaginase doses.
• Seven patients experienced neutropenic infections; two died from septicemia.
• Hyperglycemia resolved in all patients within 12 days; reinduction therapy showed lower incidence.

Conclusions:

• Hyperglycemia is a frequent complication of L-asparaginase in ALL induction.
• Close monitoring for hyperglycemia is essential to prevent treatment delays.
• Early detection and management of hyperglycemia can improve ALL treatment outcomes.